Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;9(13):4603-4612.
doi: 10.1002/cam4.3088. Epub 2020 May 6.

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer

Daniel A Goldstein  1   2   3 , Chen Mayer  4 , Tzippy Shochat  5 , Daniel Reinhorn  1   2 , Assaf Moore  1   2 , Michal Sarfaty  1   2 , Rinat Yerushalmi  1   2 , Hadar Goldvaser  1   2
Affiliations

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer

Daniel A Goldstein et al. Cancer Med. 2020 Jul.

Abstract

Background: Decision-making regarding adjuvant chemotherapy for early-stage breast cancer can be guided by genomic assays such as OncotypeDX. The concordance of expected clinical decisions guided by OncotypeDX and prognostication online tools such as PREDICT is unknown.

Methods: We performed a retrospective single-center cohort study comprising all women with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative, node negative disease, whose tumors were sent for OncotypeDX analysis. Expected decision on adjuvant chemotherapy was evaluated using OncotypeDX and using PREDICT. The concordance between these two tools was calculated. The impact on concordance of prespecified features was assessed, including age, tumor size, intensity of ER and progesterone receptor (PR), grade, Ki67 and perineural and lymphovascular invasion.

Results: A total of 445 women were included. Overall concordance was 75% (K = 0.284). The concordance was significantly higher for grade 1 disease compared to grade 2-3 (93% vs 72%, P < .001), tumor ≤ 1 cm compared to >1 cm (85% vs 72%, P = .009), PR positive compared to PR negative (78% vs 58%, P < .001) and ki67 < 10% compared to ≥10% (92% vs 63%, P < .001). The intensity of ER and the presence of perineural or lymphovascular invasion had no significant impact on concordance.

Conclusions: Compared to PREDICT, using OncotypeDx in node negative, ER positive disease is expected to change the clinical decision in a quarter of patients. The concordance between OncotypeDx and PREDICT is influenced by pathological features. In patients with very low risk, treatment decisions may be made based solely on clinical risk assessment.

Keywords: adjuvant; breast cancer; genomic assays; oncotype; predict tool.

PubMed Disclaimer

Conflict of interest statement

Moore declared honorarium payment from MSD. Sarfaty declared honorarium payment from Roche, Novartis, and MSD. Yerushalmi declared consulting fee from Roche, Pfizer, and Novartis. Invited speaker from Roche, Teva, Medison, MSD, Astra‐Zeneca, and Novartis. Goldvaser declared honorarium payment from Roche, Pfizer, Novartis, Oncotest. The other authors have no conflict of interest to declare.

Figures

FIGURE 1
FIGURE 1
Patients selection
FIGURE 2
FIGURE 2
Impact of histo‐pathological variables on concordance
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67:439‐448. - PubMed
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG ), Peto R, Davies C, Godwin J, et al. Comparison between different polychemotherapy regimens for early breast cancer: meta‐analyses of long‐term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432‐444. - PMC - PubMed
    1. Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684‐1691. - PubMed
    1. Pan H, Gray R, Braybrooke J, et al.; EBCTCG . 20‐Year risks of breast‐cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836‐1846. - PMC - PubMed
    1. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population‐based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005;20:2716‐2725. - PubMed

MeSH terms